Drug Profile
Research programme: nanoparticle cardiovascular therapeutics - NanoForm Cardiovascular Therapeutics
Alternative Names: NanoActive™ cardiovascular therapiesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NanGenex
- Developer NanoForm Cardiovascular Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom
- 15 Apr 2010 Preclinical trials in Cardiovascular disorders in United Kingdom (unspecified route)